BMY Balance Sheet

Click line-items for a historical chart and %
Current Assets:
Cash and cash equivalents 1.66B
Marketable securities 1.17B
Receivables 3.08B
Inventories 1.66B
Deferred income taxes 1.6B
Prepaid expenses and other 355M
Total Current Assets 9.52B
Property, plant and equipment 5.33B
Goodwill 7.64B
Other intangible assets 8.78B
Deferred income taxes 203M
Marketable securities 3.52B
Other assets 904M
Total Assets 35.9B
Current Liabilities:
Short-term borrowings 0
Accounts payable 2.2B
Accrued expenses 2.57B
Deferred income 825M
Accrued rebates and returns 1.05B
U.S. and foreign income taxes payable 193M
Dividends payable 606M
Total Current Liabilities 8.28B
Pension, postretirement, and postemployment liabilities 1.88B
Deferred income 4.02B
U.S. and foreign income taxes payable 648M
Other liabilities 475M
Long-term debt 6.57B
Total Liabilities 22.26B
Commitments and contingencies (Note 14) 0
Bristol-Myers Squibb Company Shareholders' Equity:
Preferred stock, $2 convertible series, par value $1 per share: Authorized 10 million shares; issued and outstanding 5,268 in 2011 and 5,269 in 2010, liquidation value of $50 per share 0
Common stock, par value of $0.10 per share: Authorized 4.5 billion shares; 2.2 billion issued in both 2011 and 2010 221M
Capital in excess of par value of stock 2.69B
Accumulated other comprehensive loss -3.2B
Retained earnings 32.73B
Less cost of treasury stock - 500 million common shares in 2011 and 501 million in 2010 -18.82B
Total Bristol-Myers Squibb Company Shareholders' Equity 13.62B
Noncontrolling interest 15M
Total Equity 13.64B
Total Liabilities and Equity 35.9B

Entities mentioned with BMY

View All Entities